Interim Report 1 January - 30 June 2004
- Promising pre-clinical data for BioInvent’s cancer project: In laboratory experiments the Company’s antibodies inhibit important elements in vessel formation. - Important milestone reached in BioInvent's project to find treatment for joint diseases. A success fee will therefore be paid to Cartela. - A candidate drug for toxicology studies within the HIV project chosen at the end of March. - A development and production agreement entered into with a new customer, Orbus Medical Technology, Inc., USA. - Net revenues for January-June 2004: SEK 29.0 million (33.9). - Cash flow from current